……的早期试验
Early-Phase Trials in .
作者信息
Stinchcombe Thomas E, Fleming Gini F, Craddock Charles, Ko Andrew H, O'Reilly Eileen M, Maki Robert G
机构信息
Duke Cancer Institute, Duke University School of Medicine, Durham, NC.
UChicago Medicine, Chicago, IL.
出版信息
J Clin Oncol. 2025 Jul;43(19):2139-2141. doi: 10.1200/JCO-25-00548. Epub 2025 May 22.
Abstract
In the article that accompanies this editorial, a well-designed trial confirmed that hearing can be protected through use of transtympanic thiosulfate injections in patients who receive high dose cisplatin with curative intent. In this editorial, members of the editorial board outline aspects of what constitutes high quality early phase trials with the goal of providing guidance for future JCO submissions.
摘要
在随本社论刊发的文章中，一项设计精良的试验证实，对于接受大剂量顺铂进行根治性治疗的患者，通过鼓室内注射硫代硫酸盐可保护听力。在本社论中，编辑委员会成员概述了构成高质量早期试验的各个方面，旨在为未来向《临床肿瘤学杂志》投稿提供指导。
相似文献
1
Early-Phase Trials in .……的早期试验
J Clin Oncol. 2025 Jul;43(19):2139-2141. doi: 10.1200/JCO-25-00548. Epub 2025 May 22.
2
Assessment of whether use of a professional medical writer is associated with time to publication of papers reporting phase III oncology clinical trials in two high-impact general medicine journals.评估在两家高影响力的普通医学期刊上，使用专业医学撰写人员是否与报告肿瘤学III期临床试验的论文发表时间相关。
Curr Med Res Opin. 2025 May;41(5):887-893. doi: 10.1080/03007995.2025.2505697. Epub 2025 May 23.
3
Evaluation of the quality of the reporting of phase II clinical trials in oncology: A systematic review.评价肿瘤学 II 期临床试验报告质量的系统评价。
Crit Rev Oncol Hematol. 2018 May;125:78-83. doi: 10.1016/j.critrevonc.2018.02.014. Epub 2018 Mar 10.
4
Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials.加速肿瘤学药物研发的未来：联盟在精准肿瘤学早期临床试验交付中的作用。
J Clin Oncol. 2025 Feb 20;43(6):735-747. doi: 10.1200/JCO-24-01534. Epub 2025 Jan 14.
5
Reporting of harms outcomes: a comparison of journal publications with unpublished clinical study reports of orlistat trials.不良事件结果的报告：奥利司他试验的期刊发表文章与未发表临床研究报告的比较
Trials. 2016 Apr 22;17(1):207. doi: 10.1186/s13063-016-1327-z.
6
Exclusion of people from oncology clinical trials based on functional status.基于功能状态将患者排除在肿瘤学临床试验之外。
Clin Trials. 2025 Jun;22(3):367-373. doi: 10.1177/17407745241304114. Epub 2025 Jan 2.
7
Defining the publication source of high-quality evidence in urology: an analysis of EvidenceUpdates.界定泌尿外科高质量证据的出版来源：对“证据更新”的分析
BJU Int. 2016 Jun;117(6):861-6. doi: 10.1111/bju.13392. Epub 2016 Jan 9.
8
Trends in the use and role of biomarkers in phase I oncology trials.生物标志物在肿瘤学I期试验中的应用趋势及作用
Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6719-26. doi: 10.1158/1078-0432.CCR-06-2860.
9
Evaluating the role of phase I expansion cohorts in oncologic drug development.评估I期扩展队列在肿瘤药物研发中的作用。
Invest New Drugs. 2017 Feb;35(1):108-114. doi: 10.1007/s10637-016-0394-z. Epub 2016 Oct 7.
10
Confidence intervals and survival estimates: a systematic review of 3 oncology journals.置信区间与生存估计：对三本肿瘤学期刊的系统评价
Am J Clin Oncol. 2006 Aug;29(4):405-7. doi: 10.1097/01.coc.0000227525.96972.2f.
本文引用的文献
1
Randomized Phase Ib Clinical Trial of DB-020 Intratympanic Injections to Reduce High-Dose Cisplatin Ototoxicity.DB-020鼓室内注射以降低高剂量顺铂耳毒性的随机1b期临床试验。
J Clin Oncol. 2025 Jul;43(19):2155-2163. doi: 10.1200/JCO.24.00905. Epub 2025 May 22.
2
HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With Alterations: A Phase Ia Dose-Escalation Study.HER2选择性酪氨酸激酶抑制剂宗格替尼（BI 1810631）用于治疗具有特定改变的晚期/转移性实体瘤患者：一项Ia期剂量递增研究。
J Clin Oncol. 2025 Apr 10;43(11):1337-1347. doi: 10.1200/JCO-24-01727. Epub 2025 Mar 3.
3
Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in -Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study.NAPORAFENIB 联合曲美替尼治疗 - 突变型黑色素瘤的初步疗效证据：一项 Ib 期、开放标签研究扩展臂的结果。
J Clin Oncol. 2023 May 10;41(14):2651-2660. doi: 10.1200/JCO.22.02018. Epub 2023 Mar 22.
4
Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study.Magrolimab 联合阿扎胞苷治疗高危骨髓增生异常综合征患者的 Ib 期研究的最终结果。
J Clin Oncol. 2023 May 20;41(15):2815-2826. doi: 10.1200/JCO.22.01794. Epub 2023 Mar 8.
5
Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study.塔拉拉单抗，一种首创的 DLL3 靶向双特异性 T 细胞衔接器，用于复发性小细胞肺癌：一项开放标签、I 期研究。
J Clin Oncol. 2023 Jun 1;41(16):2893-2903. doi: 10.1200/JCO.22.02823. Epub 2023 Jan 23.
6
A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas.在晚期脂肪肉瘤、实体瘤或淋巴瘤患者中进行的 Milademetan（一种 MDM2 抑制剂）的首次人体 I 期研究。
J Clin Oncol. 2023 Mar 20;41(9):1714-1724. doi: 10.1200/JCO.22.01285. Epub 2023 Jan 20.
7
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.依帕珠单抗，一种新型皮下注射 CD3xCD20 双特异性 T 细胞接合抗体，用于治疗复发/难治性大 B 细胞淋巴瘤：一项 I/II 期试验的剂量扩展。
J Clin Oncol. 2023 Apr 20;41(12):2238-2247. doi: 10.1200/JCO.22.01725. Epub 2022 Dec 22.
8
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer.Telisotuzumab Vedotin 联合厄洛替尼治疗 c-Met 蛋白表达的非小细胞肺癌的 Ib 期研究。
J Clin Oncol. 2023 Feb 10;41(5):1105-1115. doi: 10.1200/JCO.22.00739. Epub 2022 Oct 26.
9
Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients.改善肿瘤药物开发中使用的剂量优化流程，以最大限度地降低毒性并使患者受益。
J Clin Oncol. 2022 Oct 20;40(30):3489-3500. doi: 10.1200/JCO.22.00371. Epub 2022 Sep 12.
10
Early-Phase Oncology Trials: Why So Many Designs?早期肿瘤学试验：为何有如此多的设计？
J Clin Oncol. 2022 Oct 20;40(30):3529-3536. doi: 10.1200/JCO.21.02493. Epub 2022 Aug 12.
Zotero 插件